BSc, MSc, FIBMS
Principal Lecturer, Biomedical Science; Head of Biomedical Sciences
Department of Life & Sports Sciences
School of Science
Paul Dyer, having received his BSc Hons in Biomedical Science (University of Bradford, 1997), joined Barts and The London NHS Trust, qualifying as an HCPC registered biomedical scientist (Haematology and Blood Transfusion) in 1999. In 2001, he completed an MSc (Haematology and Blood Transfusion), and is a registered Fellow of the Institute of Biomedical Science (FIBMS).
Paul specialised in stem cell and bone marrow processing, progressing to management level in 2002. During this time he was responsible for the development and management of a GMP compliant facility for the processing of human materials for therapeutic purposes. His academic career began in 2004, when he joined North East Surrey College of Technology (NESCOT) as a lecturer in haematology and blood transfusion, teaching at both undergraduate and postgraduate levels.
In 2006 he joined the University of Greenwich as a senior lecturer in biomedical science, becoming Principal Lecturer and Head of Biomedical Sciences in April 2012. Currently Paul is completing a PhD entitled "Development of a Protein-Based Antisense Delivery Platform on Anthrax Toxin".
Responsibilities within the university
- BSc Hons Biomedical Science
- Introduction to Medical Science
- Professional Practice in Biomedical Science
- Haematology and Blood Transfusion
- Advanced and Clinical Immunology
- Medical Biochemistry
- Cell and Microbial Biology
- Fellow of the Institute of Biomedical Science (FIBMS)
Novel protein based drug delivery systems
The delivery of macromolecules to the cytosol of a cell has been, and continues to be, a significant challenge for molecules such as protein, DNA and RNA. A number of protein toxins have been previously shown to mediate entry to the cytosol whereby they can exert their toxic effect upon the cell.
The development of attenuated toxins to mediate cytosolic delivery of therapeutic macromolecules has the potential to treat a variety of diseases at the molecular level.
Oral vaccine delivery system
The method of delivery of vaccines targeting a variety of common diseases is a worldwide problem. Cold chain storage presents a significant challenges in developing nations. The principle routes of administration for current vaccines include subcutaneous and intramuscular injections. The development of safe and effective oral based vaccine using attenuated toxins to mediate translocation across gut epithelia is of interest.
Additionally, coating protein loaded silica nanoparticles with an enteric coat provides protection against the low pH and proteases commonly found in the stomach, whilst maintaining the integrity of the protein delivery system. This has the potential to mitigate against the high cost of cold chain storage and vaccine administration providing an opportunity to prevent diseases common to developing nations.
- Clinical biochemistry, haematology and pathology training for the pharmaceutical industry.
Griffiths, Peter C.,
Murphy, Damien M.,
Richardson, Simon C.W.,
and Ferruti, Paolo (2013) Self-assembled PAA-based nanoparticles as potential gene and protein delivery systems.
Dyer, Paul D.R.
and Richardson, Simon C.W. (2011) Delivery of biologics to select organelles – the role of biologically active polymers.
Dyer, Paul D.R.,
Kotha, Arun K.,
Pettit, Marie W.
and Richardson, Simon C.W. (2013) Imaging select mammalian organelles using fluorescent microscopy: application to drug delivery.